Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acomplia SERENADE Data Is Music To Sanofi’s Ears

This article was originally published in The Pink Sheet Daily

Executive Summary

Results of the study of rimonabant in type 2 diabetes patients shows improvements in blood sugar, weight and other risk factors.

You may also be interested in...



Sanofi Withdraws Zimulti NDA For Weight Loss

Company cites confusion over concerns raised by the Endocrinologic and Metabolic Drugs Advisory Committee, which voted against approval June 13.

Sanofi Withdraws Zimulti NDA For Weight Loss

Company cites confusion over concerns raised by the Endocrinologic and Metabolic Drugs Advisory Committee, which voted against approval June 13.

Acomplia User Fee Date For Weight Loss Is April 26

Sanofi-Aventis has not determined a timetable for responding to FDA’s “not approvable” letter for a smoking cessation claim.

Related Content

Topics

UsernamePublicRestriction

Register

PS063627

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel